1-7 of 7
Emily M. Huebner
Close
Sort by
Journal Articles

Infectious Complications after Intensive Chemotherapy with CLAG-M or '7+3' for Adults with Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Carla S. Walti, Anna B. Halpern, Hu Xie, E. Lisa Chung, Kelda M. Gardner, Emily M. Huebner, Colleen Delaney, Catherine Liu, Steven A. Pergam, Guang-Shing Cheng, Louise E. Kimball, Wendy M. Leisenring, Michael Boeckh, Roland B. Walter, Joshua A. Hill
Journal: Blood
Blood (2021) 138 (Supplement 1): 2339.
https://doi.org/10.1182/blood-2021-144908
Published: 2021
Journal Articles

Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

Anna B. Halpern, MD, Megan Othus, PhD, Kelda Gardner, PA-C, Genevieve Alcorn, Mary-Elizabeth M. Percival, MD, Emily M Huebner, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Paul C. Hendrie, MD PhD, Vivian G. Oehler, MD, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS
Journal: Blood
Blood (2019) 134 (Supplement_1): 1364.
https://doi.org/10.1182/blood-2019-123542
Published: 2019
Journal Articles

Developing Models to Predict Intensive Care Unit Admission and Mortality for Adults with Acute Myeloid Leukemia (AML)

Anna B Halpern, MD, Megan Othus, PhD, Emily M Huebner, Roland B. Walter, MD PhD, Gary H. Lyman, MD MPH, FRCP
Journal: Blood
Blood (2017) 130 (Supplement 1): 3857.
https://doi.org/10.1182/blood.V130.Suppl_1.3857.3857
Published: 2017
Journal Articles

G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (GCLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Grade Myeloid Neoplasms: Final Results from a Phase 1/2 Trial

Anna B Halpern, MD, Emily M Huebner, Megan Othus, PhD, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Mary-Elizabeth M. Percival, MD, Paul C. Hendrie, MD PhD, Kelda M Gardner, PA-C, Sarah A Buckley, MD, Elihu H. Estey, MD, Roland B. Walter, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 149.
https://doi.org/10.1182/blood.V130.Suppl_1.149.149
Published: 2017
Journal Articles

A Comparison of Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Treated on Versus Off Study

Sarah A. Buckley, MD, Mary-Elizabeth M. Percival, MD, Megan Othus, PhD, Anna B. Halpern, MD, Emily M Huebner, Carole Shaw, Paul C. Hendrie, MD PhD, Mazyar Shadman, MD MPH, Pamela S. Becker, MD PhD, Roland B. Walter, MD PhD, Elihu H. Estey, MD
Journal: Blood
Blood (2016) 128 (22): 2787.
https://doi.org/10.1182/blood.V128.22.2787.2787
Published: 2016
Journal Articles

A Phase 1/2 Study of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Anna B. Halpern, MD, Megan Othus, PhD, Emily M Huebner, Kaysey F. Orlowski, Bart L. Scott, MD, Heather A. Smith, PA-C, Pamela S. Becker, MD PhD, Mary-Elizabeth M. Percival, MD, Paul C. Hendrie, MD PhD, Andrea M. Perdue, PA-C, Tara L. Chen, PharmD, BCOP, Sarah A. Buckley, MD, Harry P. Erba, MD PhD, Elihu H. Estey, MD, Roland B. Walter, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1068.
https://doi.org/10.1182/blood.V128.22.1068.1068
Published: 2016
Journal Articles

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): Final Results from a Phase 1/2 Study

Anna B. Halpern, MD, Sarah A. Buckley, MD, Megan Othus, PhD, Emily M Huebner, Kaysey F. Orlowski, Bart L Scott, MD, Andrea M. Perdue, PA-C, Heather A. Smith, PA-C, Pamela S. Becker, MD PhD, Paul C. Hendrie, MD PhD, Stephanie Cassone, MSN, FNP-BC, Tara L. Chen, PharmD, BCOP, Derek L. Stirewalt, Elihu H. Estey, MD, Roland B. Walter, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1064.
https://doi.org/10.1182/blood.V128.22.1064.1064
Published: 2016